18F-Fluoromisonidazole in tumor hypoxia imaging
Metrics: PDF 772 views | HTML 1606 views | ?
Zuoyu Xu1,2, Xiao-Feng Li1,2, Hongyan Zou1, Xilin Sun1,2 and Baozhong Shen1,2
1Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China
2TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Baozhong Shen, email: firstname.lastname@example.org
Xilin Sun, email: email@example.com
Keywords: hypoxia, 18F-Fluoromisonidazole, PET, tumor
Received: June 28, 2017 Accepted: September 21, 2017 Published: October 07, 2017
Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. 18F-Fluoromisonidazole positron emission tomography (18F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between 18F-FMISO PET and other detection methods, current applications of 18F-FMISO PET and the development prospects of this imaging technology.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.